IMAGE: Bacillus bacteria, marked with green fluorescence, changed its growth pattern around other members of the THOR community, spreading around and over other bacteria. view more Credit: Gabriel Lozano and Jo Handelsman MADISON, Wis. — “Microbial communities run the world,” says Jo Handelsman, director of the Wisconsin Institute for Discovery at the University of Wisconsin-Madison. “People…
IMAGE: This is Meghna Tare, UTA chief sustainability officer. view more Credit: UT Arlington What began as a brainstorming session last year about how to unify sustainability efforts across North Texas is now the North Texas Regional Center of Expertise, or RCE, thanks to efforts led by Meghna Tare, University of Texas at Arlington chief sustainability…
NHS-approved PARP inhibitor therapy found to boost the body’s immune response Drugs could be used to increase number of patients who respond to immunotherapies Treatment developed for ovarian and breast cancers could also work in some lung cancers Precision cancer drugs called PARP inhibitors have a previously unknown ability to boost the immune system, and…
IMAGE: Predictions of antimicrobial abundance in all countries and territories in the world. Map coloured according to predicted abundance of antimicrobial from light blue (low abundance) to dark blue (high abundance). view more A comprehensive analysis of sewage collected in 74 cities in 60 countries has yielded the first, comparable global data, which show the levels…
IMAGE: Claire Tugault-Lafleur, a postdoctoral fellow in UBC’s food, nutrition and health program, was lead author of the study. view more Credit: UBC Faculty of Land & Food Systems Two surveys taken 11 years apart show a 13-per-cent decrease in the amount of fruit and vegetables being consumed by Canadians, new University of British Columbia research…
NEW YORK, NY (March 8, 2019)–TB Alliance’s new drug application (NDA) for the novel tuberculosis (TB) drug candidate pretomanid has been accepted for review by the United States Food and Drug Administration (FDA). The application is for the use of pretomanid as part of a new regimen, in combination with bedaquiline and linezolid, for the…